Progenics’ Azedra gets FDA approval for rare adrenal gland tumors

This article was originally published here

The approval is for the intravenous use of the Azedra injection in patients whose adrenal gland tumors are unresectable and have spread beyond the original tumor site and

The post Progenics’ Azedra gets FDA approval for rare adrenal gland tumors appeared first on Pharma Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply